Cardiac involvement is the leading cause of morbidity and mortality in systemic amyloidosis [1] . It occurs in about 50% of patients with systemic light chain (AL) amyloidosis and is the dominant clinical feature in patients with wild-type transthyretin (ATTR) amyloidosis and many genetic variant forms of the latter. Accurate identification and staging of cardiac amyloidosis is the crucial first step in management of these patients, involving confirmation of amyloid deposits, identification of fibril type, and evaluation of the extent and severity of amyloid related organ damage.
Cardiovascular magnetic resonance (CMR) has unique advantages in identifying cardiac involvement in systemic amyloidosis. CMR provides information about cardiac structure and function but most importantly informs us on tissue composition. CMR leverages its intrinsic capacity to characterize tissue on the basis of fundamental MR properties (T1 and T2), and these intrinsic properties can be accentuated by administration of gadolinium-based contrast agents. The latest MR techniques for evaluating late gadolinium enhancement (LGE) provide images that are virtually pathognomonic in AL and ATTR cardiac amyloidosis [2] with excellent diagnostic accuracy.
Recently the role of CMR in systemic amyloidosis has evolved beyond just diagnostic utility [3] [4] [5] [6] [7] . CMR tracks the continuum of amyloid accumulation as determined by the transmurality of LGE pattern, progressing from normal through subendocardial to transmural LGE. This has greatly elucidated how amyloid infiltration leads to dysfunction and has highlighted the potential role of LGE as a new prognostic marker that is directly linked to the basic pathogenic mechanism underlying amyloid cardiomyopathy [3] [4] [5] [6] [7] .
In this issue of iJACC, Raina et al [8] However when analyzing the differences in LGE between AL and ATTR, the transmural LGE pattern was more prevalent in ATTR than AL, yet the mortality was different across patients with similar degrees of infiltration: patients with AL amyloidosis and transmural LGE were more likely to die than ATTR patients with the same LGE extent. This has important implications.
Cardiac amyloidosis is an exemplar of infiltrative disease: amyloid deposits can account for more than one-half of total myocardial mass, but amyloid cardiomyopathy is not just about infiltration. The observation that mortality is greater in AL than ATTR in the face of an apparently similar degree of amyloid CMR has great potential to reshape assessment of patients with cardiac amyloidosis through LGE and T1 mapping. These biomarkers are key to understanding the pathophysiology of cardiac amyloidosis and to characterizing the evidently differing effects of ATTR and AL amyloid deposition. The next challenge will be to implement the transition of these biomarkers into more standardized methodologies and then assess their robustness in the wider clinical environment.
Disclosure: No conflict of interest to disclose

